Merck-Moderna Therapy Shines in Landmark Melanoma Trial
A groundbreaking Phase III trial has successfully demonstrated the efficacy of Merck and Moderna's individualized neoantigen therapy, intismeran autogene. The mRNA-based treatment, which combines with Merck's Keytruda (pembrolizumab), showed a statistically significant improvement in both recurrence-free survival and distant metastasis-free survival for patients with high-risk resected cutaneous melanoma.
The INTerpath-001 trial enrolled 1,137 patients and randomized them 2:1 to receive either the combination of intismeran and Keytruda or Keytruda alone. The result marks the first Phase III success for any individualized neoantigen therapy and provides confirmatory evidence that the approach can improve outcomes over pembrolizumab monotherapy in the adjuvant melanoma setting.
Merk and Moderna plan to engage with regulatory authorities on filing submissions, which would represent Moderna's first oncology product approval. The INTerpath program now spans nine Phase II and Phase III trials across various cancers, including non-small cell lung cancer (NSCLC) and bladder cancer.